COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Phase of Trial: Phase II
Latest Information Update: 14 Apr 2017
Price : $35 *
At a glance
- Drugs Aldesleukin (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms COMBAT-1
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2017 Time frame of primary end point has been changed fro 2 years to 3 years.
- 18 Jan 2017 Status changed from active, no longer recruiting to discontinued.